Answers are grounded in this paper and cite their sources.
NASH is a chronic, progressive, and increasingly problematic liver disease that has been resistant to treatment with individual therapeutics. In this study using a diet-induced mouse model of NASH, we found that the PPARδ agonist seladelpar reduced fibrosis and NASH pathology alone and in combinations with a GLP-1-R agonist (liraglutide) or an ASK1 inhibitor (selonsertib). Liver transcriptome analysis comparing each agent and coadministration suggests seladelpar should be effective in combination with a variety of therapeutics.
No takes yet. Share an insight, caveat, or question.
Choi et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: